Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus ORA TESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus ORA TESTRYL.
ANDROID 10 vs ORA-TESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Testosterone replacement therapy; binds to androgen receptors, promoting protein synthesis, muscle growth, and secondary sexual characteristic development.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Intramuscular injection: 50-100 mg every 2-4 weeks.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal half-life 2.5-3.5 hours; clinical context: requires multiple daily dosing to maintain steady-state levels
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Renal (90% as glucuronide and sulfate conjugates, 10% unchanged); Biliary/fecal (10%)
Category C
Category C
Androgen
Androgen